These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32627400)

  • 1. Improving Cancer Vaccine Efficiency by Nanomedicine.
    Cai J; Wang H; Wang D; Li Y
    Adv Biosyst; 2019 Mar; 3(3):e1800287. PubMed ID: 32627400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Strategies to Boost Cancer Vaccines.
    Li WH; Li YM
    Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.
    Cai T; Liu H; Zhang S; Hu J; Zhang L
    J Nanobiotechnology; 2021 Nov; 19(1):389. PubMed ID: 34823541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Vaccines for Cancer Immunotherapy.
    Wang J; Mamuti M; Wang H
    ACS Biomater Sci Eng; 2020 Nov; 6(11):6036-6052. PubMed ID: 33449675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Vaccine Therapies for Breast Cancer.
    Li X; Bu X
    Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
    Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X
    J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines.
    Liu J; Liew SS; Wang J; Pu K
    Adv Mater; 2022 Jan; 34(1):e2103790. PubMed ID: 34651344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality.
    Kang T; Huang Y; Zhu Q; Cheng H; Pei Y; Feng J; Xu M; Jiang G; Song Q; Jiang T; Chen H; Gao X; Chen J
    Biomaterials; 2018 May; 164():80-97. PubMed ID: 29499438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designer vaccine nanodiscs for personalized cancer immunotherapy.
    Kuai R; Ochyl LJ; Bahjat KS; Schwendeman A; Moon JJ
    Nat Mater; 2017 Apr; 16(4):489-496. PubMed ID: 28024156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review.
    Zhao J; Du G; Sun X
    J Biomed Nanotechnol; 2021 Nov; 17(11):2099-2113. PubMed ID: 34906272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 18. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy.
    Pan S; Fan R; Han B; Tong A; Guo G
    Trends Immunol; 2024 Jan; 45(1):20-31. PubMed ID: 38142147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.